The AstraZeneca logo is pictured outside the AstraZeneca office building on January 28, 2021 in Brussels as part of the Belgian coronavirus disease (COVID-19) vaccination campaign. Reuters / Johanna Geron
September 21, 2021
(Reuters) – AstraZeneca announced on Tuesday that it will invest $360 million to develop a manufacturing facility in Ireland to produce active pharmaceutical ingredients (APIs), or pharmaceutical ingredients.
The British-Swedish pharmaceutical company, which completed a $39 billion purchase of rare disease drug maker Alexion in July, has a broad portfolio of treatments for cancer, heart disease, diabetes and COVID-19 vaccines. The drug is being tested.
“The future formulation of our pharmaceutical APIs will include compounds with highly complex synthetics … This significant investment ensures that AstraZeneca’s supply network is fit for the future,” he said. AstraZeneca’s head of business and IT, Pamchen, said.
The planned investment in Dublin is expected to support late-stage development and early commercial supply, the company said, adding more sites for adding treatments such as antibody-drug conjugates and oligonucleotides. He said it can be developed.
(Reporting by Pushkala Aripak in Bangalore, Edited by Arun Koyur and Soumya Deb Chakraborty)